Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 9;119(36):e2209096119.
doi: 10.1073/pnas.2209096119. Epub 2022 Aug 15.

Reply to Zhu et al.: Implications of CHRNB1 and ERBB2 in the pathobiology of myasthenia gravis

Ruth Chia  1 , Sara Saez-Atienzar  1 , Daniel B Drachman  2 , Bryan J Traynor  1   2   3   4
Affiliations
Comment

Reply to Zhu et al.: Implications of CHRNB1 and ERBB2 in the pathobiology of myasthenia gravis

Ruth Chia et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interest statement: B.J.T. holds patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion of C9orf72 and has received research grants from The Myasthenia Gravis Foundation, the Robert Packard Center for ALS Research, the ALS Association (ALSA), the Italian Football Federation (FIGC), the Center for Disease Control and Prevention (CDC), the Muscular Dystrophy Association (MDA), Merck, and Microsoft Research. B.J.T. receives funding through the Intramural Research Program at the NIH.

Comment on

References

    1. Zhu Z., Chen X., Wang C., Cheng L., Novel genes/loci validate the small effect size of ERBB2 in patients with myasthenia gravis. Proc. Natl. Acad. Sci. U.S.A. 119, 10.1073/pnas.2207273119 (2022). - DOI - PMC - PubMed
    1. Chia R., et al. ; International Myasthenia Gravis Genomics Consortium, Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: A genome-wide association study. Proc. Natl. Acad. Sci. U.S.A. 119, e2108672119 (2022). - PMC - PubMed
    1. Altiok N., Bessereau J. L., Changeux J. P., ErbB3 and ErbB2/neu mediate the effect of heregulin on acetylcholine receptor gene expression in muscle: Differential expression at the endplate. EMBO J. 14, 4258–4266 (1995). - PMC - PubMed
    1. Si J., Luo Z., Mei L., Induction of acetylcholine receptor gene expression by ARIA requires activation of mitogen-activated protein kinase. J. Biol. Chem. 271, 19752–19759 (1996). - PubMed
    1. Fang H., et al. ; ULTRA-DD Consortium, A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nat. Genet. 51, 1082–1091 (2019). - PMC - PubMed